1. 357 Toxicity remains the key determinant of recommended phase II dose (RP2D) of anticancer agents despite increasing use of non-toxicity endpoints. (September 2015) Authors: Hansen, A.; Cook, N.; Eitan, A.; Siu, L.; Razak, A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S73 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A phase Ib trial with MK-8628/OTX015, a small molecule inhibitor of bromodomain (BRD) and extra-terminal (BET) proteins, in patients with selected advanced solid tumors. (December 2016) Authors: Massard, C.; Soria, J.C.; Stathis, A.; Delord, J.P.; Awada, A.; Peters, S.; Lewin, J.; Bekradda, M.; Rezai, K.; Zeng, Z.; Azher, H.; Perez, S.; Siu, L. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗